{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:30:51Z","timestamp":1792114251718,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This research has been partially supported by the Italian Ministry of Health Ricerca Corrente 2025."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06245-3","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T17:32:48Z","timestamp":1750699968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review"],"prefix":"10.1007","volume":"151","author":[{"given":"Roberto","family":"Rosenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Sganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sveva","family":"Mortellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Maria","family":"Iannantuono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"11","key":"6245_CR1","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, De Kouchkovsky I et al (2023) Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol 24(11):1266\u20131276. https:\/\/doi.org\/10.1016\/S1470-2045(23)00451-5","journal-title":"Lancet Oncol"},{"issue":"12","key":"6245_CR2","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/sj.embor.7401099","volume":"8","author":"MF Bachmann","year":"2007","unstructured":"Bachmann MF, Oxenius A (2007) Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 8(12):1142\u20131148. https:\/\/doi.org\/10.1038\/sj.embor.7401099","journal-title":"EMBO Rep"},{"issue":"1","key":"6245_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1096\/fasebj.13.1.123","volume":"13","author":"WP Benten","year":"1999","unstructured":"Benten WP, Lieberherr M, Giese G et al (1999) Functional testosterone receptors in plasma membranes of T cells. FASEB J off Publ Fed Am Soc Exp Biol 13(1):123\u2013133. https:\/\/doi.org\/10.1096\/fasebj.13.1.123","journal-title":"FASEB J off Publ Fed Am Soc Exp Biol"},{"issue":"8","key":"6245_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00262-008-0449-x","volume":"57","author":"M Chakraborty","year":"2008","unstructured":"Chakraborty M, Gelbard A, Carrasquillo JA et al (2008) Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother CII 57(8):1173\u20131183. https:\/\/doi.org\/10.1007\/s00262-008-0449-x","journal-title":"Cancer Immunol Immunother CII"},{"issue":"10","key":"6245_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1343774","volume":"8","author":"E Chan","year":"2018","unstructured":"Chan E, Quinn C, Hirji I et al (2018) Alternative metrics for assessing clinical benefit with immunotherapy in oncology. Oncoimmunology 8(10):e1343774. https:\/\/doi.org\/10.1080\/2162402X.2017.1343774","journal-title":"Oncoimmunology"},{"issue":"4","key":"6245_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ijrobp.2022.07.014","volume":"114","author":"S Chinniah","year":"2022","unstructured":"Chinniah S, Stish B, Costello BA et al (2022) Radiation therapy in oligometastatic prostate cancer. Int J Radiat Oncol Biol Phys 114(4):684\u2013692. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"6245_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2326-6066.CIR-22-0306","volume":"12","author":"AD Choudhury","year":"2024","unstructured":"Choudhury AD, Kwak L, Cheung A et al (2024) Randomized phase II study evaluating the addition of Pembrolizumab to Radium-223 in metastatic castration-resistant prostate cancer. Cancer Immunol Res 12(6):704\u2013718. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0306","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"6245_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14760584.2018.1506332","volume":"17","author":"JM Collins","year":"2018","unstructured":"Collins JM, Redman JM, Gulley JL (2018) Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. Expert Rev Vaccines 17(8):697. https:\/\/doi.org\/10.1080\/14760584.2018.1506332","journal-title":"Expert Rev Vaccines"},{"key":"6245_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.667658","volume":"11","author":"JHA Creemers","year":"2021","unstructured":"Creemers JHA, van der Doelen MJ, van Wilpe S et al (2021) Immunophenotyping reveals longitudinal changes in circulating immune cells during Radium-223 therapy in patients with metastatic castration-resistant prostate cancer. Front Oncol 11:667658. https:\/\/doi.org\/10.3389\/fonc.2021.667658","journal-title":"Front Oncol"},{"key":"6245_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fonc.2016.00141","volume":"6","author":"L Deloch","year":"2016","unstructured":"Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US (2016) Modern radiotherapy concepts and the impact of radiation on immune activation. Front Oncol 6:141. https:\/\/doi.org\/10.3389\/fonc.2016.00141","journal-title":"Front Oncol"},{"issue":"1","key":"6245_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.prro.2023.09.007","volume":"14","author":"C Deville","year":"2024","unstructured":"Deville C, Kamran SC, Morgan SC, Yamoah K, Vapiwala N (2024) Radiation therapy summary of the AUA\/ASTRO guideline on clinically localized prostate cancer. Pract Radiat Oncol 14(1):47\u201356. https:\/\/doi.org\/10.1016\/j.prro.2023.09.007","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"6245_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41391-023-00708-9","volume":"27","author":"F Ditonno","year":"2024","unstructured":"Ditonno F, Franco A, Manfredi C et al (2024) Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET\/CT. Prostate Cancer Prostatic Dis 27(1):29\u201336. https:\/\/doi.org\/10.1038\/s41391-023-00708-9","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"6245_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M et al (2024) [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 25(5):563\u2013571. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9","journal-title":"Lancet Oncol"},{"issue":"1","key":"6245_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2014.09.001","volume":"13","author":"SE Finkelstein","year":"2015","unstructured":"Finkelstein SE, Salenius S, Mantz CA et al (2015) Combining immunotherapy and radiation for prostate cancer. Clin Genitourin Cancer 13(1):1\u20139. https:\/\/doi.org\/10.1016\/j.clgc.2014.09.001","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"6245_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","volume":"78","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Drake CG, Beer TM et al (2020) Final analysis of the ipilimumab versus placebo following radiotherapy phase iii trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol 78(6):822\u2013830. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.032","journal-title":"Eur Urol"},{"issue":"17","key":"6245_CR16","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1158\/1078-0432.CCR-21-0063","volume":"27","author":"L Fong","year":"2021","unstructured":"Fong L, Morris MJ, Sartor O et al (2021) A phase Ib study of Atezolizumab with Radium-223 dichloride in men with metastatic castration-resistant prostate cancer. Clin Cancer Res 27(17):4746\u20134756. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0063","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6245_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","volume":"27","author":"SJ Freedland","year":"2024","unstructured":"Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI (2024) Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US medicare population. Prostate Cancer Prostatic Dis 27(2):327\u2013333. https:\/\/doi.org\/10.1038\/s41391-023-00725-8","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"6245_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41571-019-0238-9","volume":"16","author":"C Grassberger","year":"2019","unstructured":"Grassberger C, Ellsworth SG, Wilks MQ, Keane FK, Loeffler JS (2019) Assessing the interactions between radiotherapy and antitumour immunity. Nat Rev Clin Oncol 16(12):729\u2013745. https:\/\/doi.org\/10.1038\/s41571-019-0238-9","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"6245_CR19","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.4049\/jimmunol.169.7.3760","volume":"169","author":"JM Grayson","year":"2002","unstructured":"Grayson JM, Harrington LE, Lanier JG, Wherry EJ, Ahmed R (2002) Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J Immunol Baltim Md 1950 169(7):3760\u20133770. https:\/\/doi.org\/10.4049\/jimmunol.169.7.3760","journal-title":"J Immunol Baltim Md 1950"},{"issue":"9","key":"6245_CR20","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1158\/1078-0432.CCR-04-2062","volume":"11","author":"JL Gulley","year":"2005","unstructured":"Gulley JL, Arlen PM, Bastian A et al (2005) Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11(9):3353\u20133362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2062","journal-title":"Clin Cancer Res"},{"issue":"17","key":"6245_CR21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA et al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 388(17):1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2214122","journal-title":"N Engl J Med"},{"issue":"6","key":"6245_CR22","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/biomedicines10061419","volume":"10","author":"R Hannan","year":"2022","unstructured":"Hannan R, Dohopolski MJ, Pop LM et al (2022) Phase II trial of Sipuleucel-T and stereotactic ablative body radiation for patients with metastatic castrate-resistant prostate cancer. Biomedicines 10(6):1419. https:\/\/doi.org\/10.3390\/biomedicines10061419","journal-title":"Biomedicines"},{"issue":"42","key":"6245_CR23","doi-asserted-by":"publisher","first-page":"69014","DOI":"10.18632\/oncotarget.10883","volume":"7","author":"CR Heery","year":"2016","unstructured":"Heery CR, Madan RA, Stein MN et al (2016) Samarium-153-EDTMP (Quadramet\u00ae) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized phase 2 trial. Oncotarget 7(42):69014\u201369023. https:\/\/doi.org\/10.18632\/oncotarget.10883","journal-title":"Oncotarget"},{"issue":"1","key":"6245_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3322\/caac.21358","volume":"67","author":"FG Herrera","year":"2017","unstructured":"Herrera FG, Bourhis J, Coukos G (2017) Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin 67(1):65\u201385. https:\/\/doi.org\/10.3322\/caac.21358","journal-title":"CA Cancer J Clin"},{"issue":"10276","key":"6245_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S et al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet Lond Engl 397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"6245_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S et al (2024) Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol 25(1):99\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(23)00529-6","journal-title":"Lancet Oncol"},{"issue":"15","key":"6245_CR27","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.3390\/ijms23158535","volume":"23","author":"GM Iannantuono","year":"2022","unstructured":"Iannantuono GM, Torino F, Rosenfeld R et al (2022) The role of histology-agnostic drugs in the treatment of metastatic castration-resistant prostate cancer. Int J Mol Sci 23(15):8535. https:\/\/doi.org\/10.3390\/ijms23158535","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6245_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/pcan.2012.7","volume":"15","author":"M Kamrava","year":"2012","unstructured":"Kamrava M, Kesarwala AH, Madan RA et al (2012) Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer Prostatic Dis 15(3):289\u2013295. https:\/\/doi.org\/10.1038\/pcan.2012.7","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"6245_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422. https:\/\/doi.org\/10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"issue":"2","key":"6245_CR30","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/j.clgc.2017.10.010","volume":"16","author":"JW Kim","year":"2018","unstructured":"Kim JW, Shin MS, Kang Y, Kang I, Petrylak DP (2018) Immune analysis of Radium-223 in patients with metastatic prostate cancer. Clin Genitourin Cancer 16(2):e469\u2013e476. https:\/\/doi.org\/10.1016\/j.clgc.2017.10.010","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"6245_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","volume":"81","author":"EM Kwan","year":"2022","unstructured":"Kwan EM, Spain L, Anton A et al (2022) Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial. Eur Urol 81(3):253\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.011","journal-title":"Eur Urol"},{"issue":"7","key":"6245_CR32","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700\u2013712. https:\/\/doi.org\/10.1016\/S1470-2045(14)70189-5","journal-title":"Lancet Oncol"},{"issue":"8","key":"6245_CR33","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/cancers16081480","volume":"16","author":"W Lautert-Dutra","year":"2024","unstructured":"Lautert-Dutra W, Melo CM, Chaves LP et al (2024) Investigating the role of SNAI1 and ZEB1 expression in prostate cancer progression and immune modulation of the tumor microenvironment. Cancers 16(8):1480. https:\/\/doi.org\/10.3390\/cancers16081480","journal-title":"Cancers"},{"issue":"10","key":"6245_CR34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1080\/09553002.2021.1956002","volume":"97","author":"CN Leung","year":"2021","unstructured":"Leung CN, Howell DM, Howell RW (2021) Radium-223 dichloride causes transient changes in natural killer cell population and cytotoxic function. Int J Radiat Biol 97(10):1417\u20131424. https:\/\/doi.org\/10.1080\/09553002.2021.1956002","journal-title":"Int J Radiat Biol"},{"issue":"6","key":"6245_CR35","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/jnci\/djaa021","volume":"112","author":"RA Madan","year":"2020","unstructured":"Madan RA, Antonarakis ES, Drake CG et al (2020) Putting the pieces together: completing the mechanism of action Jigsaw for Sipuleucel-T. JNCI J Natl Cancer Inst 112(6):562\u2013573. https:\/\/doi.org\/10.1093\/jnci\/djaa021","journal-title":"JNCI J Natl Cancer Inst"},{"key":"6245_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108707","volume":"226","author":"J Majidpoor","year":"2021","unstructured":"Majidpoor J, Mortezaee K (2021) The efficacy of PD-1\/PD-L1 blockade in cold cancers and future perspectives. Clin Immunol 226:108707. https:\/\/doi.org\/10.1016\/j.clim.2021.108707","journal-title":"Clin Immunol"},{"issue":"6","key":"6245_CR37","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-20-4476","volume":"27","author":"CH Marshall","year":"2021","unstructured":"Marshall CH, Fu W, Wang H et al (2021) Randomized phase II trial of Sipuleucel-T with or without Radium-223 in men with bone-metastatic castration-resistant prostate cancer. Clin Cancer Res 27(6):1623\u20131630. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4476","journal-title":"Clin Cancer Res"},{"issue":"18","key":"6245_CR38","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.3390\/cancers14184530","volume":"14","author":"M Miljanic","year":"2022","unstructured":"Miljanic M, Montalvo S, Aliru M et al (2022) The evolving interplay of SBRT and the immune system, along with future directions in the field. Cancers 14(18):4530. https:\/\/doi.org\/10.3390\/cancers14184530","journal-title":"Cancers"},{"issue":"1","key":"6245_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10654-019-00576-5","volume":"35","author":"T Muka","year":"2020","unstructured":"Muka T, Glisic M, Milic J et al (2020) A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. Eur J Epidemiol 35(1):49\u201360. https:\/\/doi.org\/10.1007\/s10654-019-00576-5","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"6245_CR40","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3390\/biomedicines13051179","volume":"13","author":"NP Murray","year":"2025","unstructured":"Murray NP (2025) Immunomodulation and immunotherapy for patients with prostate cancer: an up-to-date review. Biomedicines 13(5):1179. https:\/\/doi.org\/10.3390\/biomedicines13051179","journal-title":"Biomedicines"},{"issue":"2","key":"6245_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295837","volume":"19","author":"K Mustafa","year":"2024","unstructured":"Mustafa K, Han Y, He D et al (2024) Poly-(ADP-ribose) polymerases inhibition by olaparib attenuates activities of the NLRP3 inflammasome and of NF-\u03baB in THP-1 monocytes. PLoS One 19(2):e0295837. https:\/\/doi.org\/10.1371\/journal.pone.0295837","journal-title":"PLoS One"},{"issue":"5","key":"6245_CR42","doi-asserted-by":"publisher","first-page":"694","DOI":"10.37349\/etat.2022.00108","volume":"3","author":"MT Palano","year":"2022","unstructured":"Palano MT, Gallazzi M, Cucchiara M et al (2022) The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors. Explor Target Anti-Tumor Ther 3(5):694\u2013718. https:\/\/doi.org\/10.37349\/etat.2022.00108","journal-title":"Explor Target Anti-Tumor Ther"},{"issue":"3","key":"6245_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"key":"6245_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1055826","author":"C Qin","year":"2022","unstructured":"Qin C, Wang J, Du Y, Xu T (2022) Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2022.1055826","journal-title":"Front Endocrinol"},{"issue":"10305","key":"6245_CR45","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG (2021) Prostate cancer. Lancet Lond Engl 398(10305):1075\u20131090. https:\/\/doi.org\/10.1016\/S0140-6736(21)00950-8","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"6245_CR46","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, De Bono J, Chi KN et al (2021) Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"6245_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110091","volume":"192","author":"PJ Saylor","year":"2024","unstructured":"Saylor PJ, Kozin SV, Matsui A et al (2024) The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 192:110091. https:\/\/doi.org\/10.1016\/j.radonc.2024.110091","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"1","key":"6245_CR48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"6245_CR49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/MOU.0000000000001115","volume":"33","author":"SF Slovin","year":"2023","unstructured":"Slovin SF (2023) Immunotherapy combinations for metastatic castration-resistant prostate cancer\u2014failed trials and future aspects. Curr Opin Urol 33(5):390. https:\/\/doi.org\/10.1097\/MOU.0000000000001115","journal-title":"Curr Opin Urol"},{"issue":"7","key":"6245_CR50","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","volume":"24","author":"SF Slovin","year":"2013","unstructured":"Slovin SF, Higano CS, Hamid O et al (2013) Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study. Ann Oncol 24(7):1813\u20131821. https:\/\/doi.org\/10.1093\/annonc\/mdt107","journal-title":"Ann Oncol"},{"issue":"10","key":"6245_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101199","volume":"4","author":"D Sridaran","year":"2023","unstructured":"Sridaran D, Bradshaw E, DeSelm C, Pachynski R, Mahajan K, Mahajan NP (2023) Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach. Cell Rep Med 4(10):101199. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101199","journal-title":"Cell Rep Med"},{"issue":"1","key":"6245_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D (2023) Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther 8(1):1\u201326. https:\/\/doi.org\/10.1038\/s41392-023-01522-4","journal-title":"Signal Transduct Target Ther"},{"key":"6245_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06705-x","author":"G T","year":"2024","unstructured":"T G, L P, A G, E G, D N, S C (2024) Targeted interleukin-2 enhances the in vivo anti-cancer activity of PluvictoTM. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-024-06705-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6245_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamaoncol.2022.4591","volume":"9","author":"R Thawani","year":"2023","unstructured":"Thawani R, Kummar S (2023) Combining PARP inhibitor with immunotherapy\u2014does the promise of preclinical data translate to clinic? JAMA Oncol 9(1):25\u201327. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4591","journal-title":"JAMA Oncol"},{"issue":"7","key":"6245_CR55","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"6245_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2018.100116","volume":"19","author":"P Twardowski","year":"2019","unstructured":"Twardowski P, Wong JYC, Pal SK et al (2019) Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treat Res Commun 19:100116. https:\/\/doi.org\/10.1016\/j.ctarc.2018.100116","journal-title":"Cancer Treat Res Commun"},{"issue":"8","key":"6245_CR57","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/biomedicines10081778","volume":"10","author":"P Xu","year":"2022","unstructured":"Xu P, Wasielewski LJ, Yang JC et al (2022) The immunotherapy and immunosuppressive signaling in therapy-resistant prostate cancer. Biomedicines 10(8):1778. https:\/\/doi.org\/10.3390\/biomedicines10081778","journal-title":"Biomedicines"},{"key":"6245_CR58","doi-asserted-by":"publisher","first-page":"1355388","DOI":"10.3389\/fimmu.2024.1355388","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Vedvyas Y, Alcaina Y, Son JY, Min IM, Jin MM (2024) Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response. Front Immunol 15:1355388. https:\/\/doi.org\/10.3389\/fimmu.2024.1355388","journal-title":"Front Immunol"},{"issue":"1","key":"6245_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, Yu J (2022) Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 7(1):1\u201334. https:\/\/doi.org\/10.1038\/s41392-022-01102-y","journal-title":"Signal Transduct Target Ther"}],"updated-by":[{"DOI":"10.1007\/s00432-025-06273-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000}}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06245-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06245-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06245-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:30:14Z","timestamp":1757997014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06245-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["6245"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06245-3","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the given and family names of the author group. In addition, the abstract and affiliation for Marta Scorsetti, Ornella Garrone, Giovanni Maria Iannantuono, Elias Chandran, Michele Ghidini, and Ciro Franzese has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00432-025-06273-z","URL":"https:\/\/doi.org\/10.1007\/s00432-025-06273-z","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"195"}}